Acumed LLC
$3.5M 4,053 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. reported $3,504,002.94 across General Payments, Research, and Ownership to 89 physicians and teaching hospitals across 94 transactions.
- $3.5M
- All-tracks total
- 94
- Transactions
- 89
- Recipients
- −$1.3M
- General Payments vs PY2023
Sumitomo Pharma Co., Ltd. reported $3,504,002.94 across all CMS Open Payments tracks (General + Research + Ownership) to 89 physicians and teaching hospitals in Program Year 2024 - ranking #331 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $121,871.94, averaging $39.4K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer sumitomo-pharma-co-ltd Sumitomo Pharma Co., Ltd.
$3.5M · #331/1,925 · 0.0% industry · PY2024
- TOT $3.5M
- RANK #331
- SHARE 0.0%
- TXN 94
- RCP 89
- CAT 5
- GEN $121.9K
- ΔGEN −$1.3M
- TOP1 36.9%
- PY 2024
Volume peers
Nearest volume peer: Acumed LLC ($3.5M)
Sumitomo Pharma Co., Ltd. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Sumitomo Pharma Co., Ltd.'s CMS-reported General Payments decreased by $1.3M (−91.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SUMITOMO PHARMA CO., LTD.PY2023: SUMITOMO PHARMA CO., LTD.PY2024: Sumitomo Pharma Co., Ltd.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,426,023.13
- PY2024
- $121,871.94
What the Data Shows for Sumitomo Pharma Co., Ltd.
Averaging $37.3K per transaction and $39.4K per recipient, Sumitomo Pharma Co., Ltd.'s Program Year 2024 total comes to $3,504,002.94 across 94 transactions and 89 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #331 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
"Charitable Contribution" leads the 5-category general-payment breakdown below at $44.9K (36.9% of General Payments, 1 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Charitable Contribution" leads Sumitomo Pharma Co., Ltd.'s 5-category general-payment breakdown at $44.9K, 36.9% of the reported total.
Sumitomo Pharma Co., Ltd. reports 5 general-payment categories - the top three are Charitable Contribution (36.9%), Travel and Lodging (33.5%), and Honoraria (17.2%). The remaining 2 categories make up 12.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Sumitomo Pharma Co., Ltd. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Charitable Contribution | $44.9K | 1 | 36.9% |
| Travel and Lodging | $40.9K | 55 | 33.5% |
| Honoraria | $21.0K | 8 | 17.2% |
| Consulting Fee | $14.5K | 15 | 11.9% |
| Food and Beverage | $555.57 | 10 | 0.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $105,264.81 (86.4%) of $121,871.94 in this company's General Payments records across 12 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Sumitomo Pharma Co., Ltd.
The five named recipients with the highest reported General Payments from this company
- 1
Massachusetts Eye And Ear Infirmary
$44,947.00 across 1 reported transactions
- 2
Naval G Daver
$31,482.90 across 17 reported transactions
- 3
Rohit Kulkarni
$14,830.31 across 9 reported transactions
- 4
Akira Sawa
$7,021.03 across 33 reported transactions
- 5
John M. Kane
$6,983.57 across 10 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Sumitomo Pharma Co., Ltd.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Sumitomo Pharma Co., Ltd..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Sumitomo Pharma Co., Ltd..
Showing 6 of 1,924 companies with CMS-reported payment data.
Amplify Surgical, Inc.
$3.5M 66 recipients
Compare payment profiles
Kowa Company, Ltd.
$3.5M 0 recipients
Compare payment profiles
Averitas Pharma Inc.
$3.5M 14,332 recipients
Compare payment profiles
Ethicon Inc.
$3.5M 2,774 recipients
Compare payment profiles
Puma Biotechnology, Inc.
$3.5M 5,232 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.